|
"bray v"的相關文件
顯示項目 1-4 / 4 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-02 |
Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation–positive NSCLC: An open-label Phase 2 trial (ILLUMINATE)
|
Lee, CK;Liao, BC;Subramaniam, S;Chiu, CH;Mersiades, AJ;Ho, CC;Brown, C;Lai, CL;Hughes, BGM;Yang, TY;O'Byrne, K;Luo, YH;Yip, S;Ho, CL;Bray, V;Su, WC;Moore, M;Feng, WL;Bai, YY;Ford, K;Cummins, MM;Stockler, MR;Solomon, BJ;John, T;Chih-Hsin Yang, J |
| 國家衛生研究院 |
2023-11 |
ILLUMINATE: Efficacy and safety of durvalumab-tremelimumab and chemotherapy in EGFR mutant NSCLC following progression on EGFR inhibitors
|
Lee, C;Liao, BC;Subramaniam, S;Chiu, CH;Mersiades, A;Ho, CC;Brown, C;Lai, CL;Hughes, BGM;Yang, TY;O'Byrne, K;Luo, YH;Yip, S;Ho, CL;Bray, V;Su, WC;Moore, M;Feng, WL;Bai, YY;Stockler, M;Solomon, B;John, T;Yang, JCH |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non?�Small Cell Lung Cancer
|
Lee C.K.; CHIH-HSIN YANG; Gralla R.J; Bray V; Links M; Gebski V; Lord S.J; Lee C.K.;Chih-Hsin Yang;Gralla R.J;Bray V;Links M;Gebski V;Lord S.J;Ding P.N; Ding P.N |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non?�Small Cell Lung Cancer
|
Lee C.K.; CHIH-HSIN YANG; Gralla R.J; Bray V; Links M; Gebski V; Lord S.J; Lee C.K.;Chih-Hsin Yang;Gralla R.J;Bray V;Links M;Gebski V;Lord S.J;Ding P.N; Ding P.N |
顯示項目 1-4 / 4 (共1頁)
1
每頁顯示[10|25|50]項目
|
